US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Emergent BioSolutions Inc. Common Stock
(NY:
EBS
)
6.330
-0.040 (-0.63%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Emergent BioSolutions Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
September 22, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
September 15, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
September 15, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
September 08, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Emergent BioSolutions (NYSE:EBS) Beats Q2 Estimates, but Stock Drops on NARCAN Impairment and Restructuring Costs
↗
August 05, 2026
Via
Chartmill
Emergent BioSolutions (NYSE:EBS) Surges After Q1 Earnings Beat and Raised Profit Outlook
↗
April 30, 2026
Via
Chartmill
Topics
Earnings
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
September 03, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
September 01, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
September 01, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
August 31, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
August 31, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
August 25, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
August 19, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 18, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
August 17, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
MCM deliveries surge but naloxone competition forces restructuring and guidance cuts.
Via
The Motley Fool
Topics
Earnings
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)
August 12, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Emergent Biosolutions Q2 Earnings Call Highlights
↗
August 08, 2026
Emergent Biosolutions (NYSE:EBS) reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S....
Via
MarketBeat
Topics
Earnings
Economy
Wondering what's happening in today's after-hours session?
↗
August 05, 2026
Via
Chartmill
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
August 05, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
August 05, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
July 22, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
June 29, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
June 04, 2026
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
May 28, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Participate in Upcoming Investor Conferences
May 20, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
May 18, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent (EBS) Q1 2026 Earnings Transcript
↗
May 01, 2026
Emergent (EBS) Q1 2026 Earnings Transcript
Via
The Motley Fool
Emergent BioSolutions Reports First Quarter 2026 Financial Results
April 30, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
April 30, 2026
From
Emergent BioSolutions
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
